RxSight (NASDAQ:RXST – Get Free Report) will likely be posting its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect RxSight to announce earnings of ($0.21) per share and revenue of $32.55 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.
RxSight Stock Performance
Shares of RxSight stock opened at $6.29 on Tuesday. The stock has a market capitalization of $260.41 million, a P/E ratio of -5.57 and a beta of 1.13. RxSight has a 52-week low of $4.48 and a 52-week high of $13.22. The stock’s 50-day simple moving average is $5.27 and its 200 day simple moving average is $6.72.
Institutional Investors Weigh In On RxSight
Several large investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. bought a new position in RxSight in the 2nd quarter worth about $28,000. Larson Financial Group LLC boosted its position in shares of RxSight by 110.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,979 shares of the company’s stock valued at $36,000 after acquiring an additional 2,089 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in shares of RxSight by 440.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,758 shares of the company’s stock worth $39,000 after purchasing an additional 3,063 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of RxSight by 156.2% in the second quarter. Tower Research Capital LLC TRC now owns 5,574 shares of the company’s stock worth $72,000 after purchasing an additional 3,398 shares during the last quarter. Finally, Aquatic Capital Management LLC increased its position in shares of RxSight by 200.3% in the third quarter. Aquatic Capital Management LLC now owns 11,043 shares of the company’s stock worth $99,000 after purchasing an additional 7,366 shares during the last quarter. Institutional investors own 78.78% of the company’s stock.
Analysts Set New Price Targets
Get Our Latest Stock Report on RXST
About RxSight
RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.
Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.
Featured Stories
- Five stocks we like better than RxSight
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.
